Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis
This is my archive
Projected Ontario budget savings from reduced long-term care utilization due to a disease-modifying Alzheimer’s treatment
Association of Adverse Events in Opioid Addiction Treatment With Quality Measure for Continuity of Pharmacotherapy
Estimating minimal clinically important differences for two scales in patients with chronic traumatic brain injury
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia
Evidence for Misspecification of a Nationally Used Quality Measure for Substance Use Treatment
